Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 8,250 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Humans Clear all
Not yet recruiting Not applicable Interventional

10 Degree C Static Storage in Heart Transplantation

NCT07818941
View directory record Official record
Conditions
Transplant, Failure, Heart, Heart Transplant, Heart Failure
Interventions
10 degree C Static Storage Cooler
Device
Lead sponsor
John Trahanas
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 30, 2026, 11:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Fiber and Fish Oil Supplements for the Prevention of Colorectal Cancer

NCT04211766
View directory record Official record
Conditions
Healthy Subject
Interventions
Dietary Fiber, Fish Oil, Comparator
Dietary Supplement · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
50 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 30, 2026, 11:33 PM EDT
Completed Phase 2 Interventional Results available

Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)

NCT02175966
View directory record Official record
Conditions
Hepatitis C
Interventions
DCV/ASV/BMS-791325, Ribavirin, Sofosbuvir, Peginterferon α-2a
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Rialto, California • Chicago, Illinois • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 30, 2026, 11:33 PM EDT
Completed Phase 1 Interventional

Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy

NCT04635995
View directory record Official record
Conditions
Cancer
Interventions
LVGN7409
Biological
Lead sponsor
Lyvgen Biopharma Holdings Limited
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 30, 2026, 11:33 PM EDT
Recruiting Phase 4 Interventional

Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis

NCT04588077
View directory record Official record
Conditions
Hepatitis B, Cirrhosis, Liver, Chronic Liver Disease
Interventions
Heplisav-B Injectable Product, 2-dose regimen, Heplisav-B Injectable Product, 3-dose regimen
Biological
Lead sponsor
Mercy Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 30, 2026, 11:33 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01

NCT06247345
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ADEL-Y01 - healty participants, Placebo - Healthy Participants, ADEL-Y01 - MCI/AD, Placebo - MCI/AD
Drug
Lead sponsor
Alzheimer's Disease Expert Lab (ADEL), Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
6
States / cities
Anaheim, California • Lady Lake, Florida • Maitland, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 30, 2026, 11:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ultrasound Analysis of Human Carpal Tunnel System

NCT02747836
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
Ultrasound of the wrist
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
257 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 30, 2026, 11:33 PM EDT
Completed Phase 1 Interventional

VRC 307: A Double-Blind, Randomized Phase I Study of the Safety and Immunogenicity of a Prime-Boost Schedule of the Investigational DNA Trivalent Influenza Vaccine, VRC-FLUDNA047-00-VP, Followed by the 2008/2009 Seasonal Influenza Trivalent Inactivat...

NCT00858611
View directory record Official record
Conditions
Influenza, Human
Interventions
VRC-FLUDNA047-00-VP, Flulaval (Registered) Seasonal Influenza Vaccine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 30, 2026, 11:33 PM EDT
Recruiting Phase 1 Interventional

A Study to Test How Well Different Doses of BI 4060107 Are Tolerated by People With Advanced Cancer (Solid Tumours)

NCT07827144
View directory record Official record
Conditions
Solid Tumours
Interventions
BI 4060107
Biological
Lead sponsor
AIMEDBIO
Government
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Irving, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 30, 2026, 11:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oral T7 Oral Testosterone in Man

NCT00842751
View directory record Official record
Conditions
Healthy Males, Male Contraceptive
Interventions
First Intervention (7 days), First Washout (7 days), Second Intervention (7 days), Third Intervention (7 days), Second wash-out period
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 30, 2026, 11:33 PM EDT
Recruiting Phase 1Phase 2 Interventional

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

NCT05768139
View directory record Official record
Conditions
Breast Cancer, Solid Tumors, Adult
Interventions
STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole, Anastrozole, Exemestane, Tamoxifen, Abemaciclib, Imlunestrant, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
28
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 30, 2026, 11:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Topical Collagen Powder for Healing of Acute Full-thickness Wounds

NCT03481907
View directory record Official record
Conditions
Wound of Skin, Wound Heal
Interventions
Nuvagen Collagen Powder
Device
Lead sponsor
Adam Friedman
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 30, 2026, 11:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™

NCT00377611
View directory record Official record
Conditions
Influenza
Interventions
Fluarix™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
3,054 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
9
States / cities
Mobile, Alabama • Delray Beach, Florida • Pembroke Pines, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 30, 2026, 11:33 PM EDT
Recruiting Phase 2 Interventional

Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

NCT02479698
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, BK Virus Infection, Human Immunodeficiency Virus, JC Virus Infection, Malignant Neoplasm, Merkel Cell Carcinoma, Merkel Cell Polyomavirus Infection, Viral Encephalitis
Interventions
Allogeneic BK-specific Cytotoxic T-lymphocytes, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 30, 2026, 11:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Oral Adenosine-triphosphate (ATP) on Human Muscle Performance

NCT01141504
View directory record Official record
Conditions
Healthy Subjects
Interventions
PeakATP 250, Placebo, PeakATP 400, PeakATP 400 plus proprietary blend
Dietary Supplement
Lead sponsor
Metabolic Technologies Inc.
Industry
Eligibility
20 Years to 30 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 10, 2012 · Synced Oct 30, 2026, 11:33 PM EDT
Completed Phase 1 Interventional

AMG 319 Lymphoid Malignancy FIH

NCT01300026
View directory record Official record
Conditions
Cancer, Chronic Lymphocytic Leukemia, Diffuse Large Cell Lymphoma, Hematologic Malignancies, Hematology, Leukemia, Low Grade Lymphoma, Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma, Oncology, Oncology Patients, T Cell Lymphoma, Tumors
Interventions
AMG 319
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Hackensack, New Jersey • Durham, North Carolina • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 30, 2026, 11:33 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

NCT05267626
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
Interventions
AU-007, Aldesleukin, Avelumab, Nivolumab
Drug
Lead sponsor
Aulos Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 30, 2026, 11:33 PM EDT
Completed Phase 2 Interventional

Capravirine (AG1549) in Combination With Viracept and Two NRTIs in HIV Infected Patients Who Failed an Initial NNRTI Containing Regimen

NCT00051844
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Capravirine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
30
States / cities
Beverly Hills, California • Long Beach, California • Newport Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 10, 2011 · Synced Oct 30, 2026, 11:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sodium Channel Expression in Human Teeth

NCT00575263
View directory record Official record
Conditions
Dental Pulp Disease
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
16 Years to 80 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2015 · Synced Oct 30, 2026, 11:33 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Accuracy Of A Novel Platelet Activity Assay In Humans On Antiplatelet Agents: Pharmacodynamics And Comparison With Light Transmission Aggregometry

NCT04822363
View directory record Official record
Conditions
Platelet Activation Testing Before/After Anti-platelet Therapy, Healthy
Interventions
Aspirin, Clopidogrel
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 30, 2026, 11:33 PM EDT
Not yet recruiting Early Phase 1 Interventional

Study to Image Inflammatory Activity of a Fluorescence Imaging Agent in Excised Human Artery Plaques

NCT06957821
View directory record Official record
Conditions
Carotid Artery Diseases, Peripheral Arterial Disease
Interventions
Pegulicianine, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 30, 2026, 11:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults

NCT00120848
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
HPV 16/18 VLP AS04
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
20 Years to 30 Years · Female only
Enrollment
776 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
17
States / cities
San Francisco, California • Augusta, Georgia • Bardstown, Kentucky + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 30, 2026, 11:33 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis

NCT00195663
View directory record Official record
Conditions
Early Rheumatoid Arthritis
Interventions
Adalimumab, Methotrexate, Adalimumab placebo, Methotrexate placebo
Biological · Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
31
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2013 · Synced Oct 30, 2026, 11:33 PM EDT
Terminated No phase listed Observational

Genetic Analysis of Brain Tumors

NCT00031538
View directory record Official record
Conditions
Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligodendroglioma, Astrocytoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 99 Years
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
3
States / cities
Bethesda, Maryland • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 30, 2026, 11:33 PM EDT